Hims & Hers Health, Inc. (HIMS) Stock Analysis
Catalyst-Driven edge
Healthcare · Drug Manufacturers - Specialty & Generic
Hold if already holding. Not a fresh buy at $26.31, but acceptable to hold if already in. Reasons: Concentration risk — Product: subscription prescription products; Analyst target reached - limited upside remaining.
Hims and Hers operates a consumer telehealth platform connecting patients to licensed providers for prescription medications and wellness products across sexual health, hair loss, weight loss, dermatology, and mental health. Revenue reached 2,347.6M in 2025, driven primarily by... Read more
Hold if already holding. Not a fresh buy at $26.31, but acceptable to hold if already in. Reasons: Concentration risk — Product: subscription prescription products; Analyst target reached - limited upside remaining. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 4.5/10, high confidence.
Passes 3/7 gates (clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductsubscription prescription products10-K Item 1A: 'we derive a substantial majority of our revenue from customers' subscription-based purchases of prescription products made available through our platform'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $26.31, but acceptable to hold if already in. Reasons: Concentration risk — Product: subscription prescription products; Analyst target reached - limited upside remaining. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Target $31.22 (+18.7%), stop $24.48 (−7.5%), A.R:R -0.9:1. Score 4.5/10, high confidence.
Take-profit target: $31.22 (+18.6% upside). Target $31.22 (+18.7%), stop $24.48 (−7.5%), A.R:R -0.9:1. Stop-loss: $24.48.
Concentration risk — Product: subscription prescription products; Analyst target reached - limited upside remaining; Leverage penalty (D/E 2.1): -1.5.
Hims & Hers Health, Inc. trades at a P/E of 51.6 (forward 19.1). TrendMatrix value score: 4.2/10. Verdict: Hold.
22 analysts cover HIMS with a consensus score of 3.5/5. Average price target: $26.
What does Hims & Hers Health, Inc. do?Hims and Hers operates a consumer telehealth platform connecting patients to licensed providers for prescription...
Hims and Hers operates a consumer telehealth platform connecting patients to licensed providers for prescription medications and wellness products across sexual health, hair loss, weight loss, dermatology, and mental health. Revenue reached 2,347.6M in 2025, driven primarily by subscription purchases of prescription products fulfilled through wholly-owned pharmacies.